Serkan Erkanli

Serkan Erkanli

Auto-generated profile, based on publicly available information

Serkan Erkanli

Acibadem University, school of medicine

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2003 in Advances in Therapy
Verified
Journal Article
Closed access
PDF file
BEBulent Erdogan
Bulent Erdogan
TBTayfun Bagis
Tayfun Bagis
OŞOrhan Şen
Orhan Şen
SESerkan Erkanli
Serkan Erkanli
NANur Altinors
Nur Altinors
BABasar Atalay
Basar Atalay

1 March 2024 in European Archives of Medical Research
Verified
Journal Article
Closed access
BKBusra Kose
Busra Kose
ÖTÖzgüç Takmaz
Özgüç Takmaz
MGMete Gungor
Mete Gungor
SESerkan Erkanlı
Serkan Erkanlı
AKAlper Koçak
Alper Koçak
ABAhmet Baykal
Ahmet Baykal

9 December 2023 in Acibadem Universitesi Saglik Bilimleri Dergisi
Verified
Journal Article
Closed access
SESuheyla Ekemen
Suheyla Ekemen
DŞDavut Şahin
Davut Şahin
STSadik Toprak
Sadik Toprak
EBEbru Bilir
Ebru Bilir
MAMeryem Akbaş
Meryem Akbaş
SESerkan Erkanlı
Serkan Erkanlı
Introduction: Cervical cancer is one of the most common cancers in women. Precancerous lesions of the cervix can be detected with the combined use of smear testing and HPV (Human Papillomavirus) testing. International guidelines have been developed to indicate at what intervals and in which situations the tests should be performed. In this study, we examined the clinical utility of screening tests in patients with histopathologically diagnosed SCC (squamous cell carcinoma) and HSIL. Metods: Between January 2022 and June 2023, 447 patients aged 19-73 years (mean 37) with cervical biopsy results of SCC and HSIL were evaluated for the use of diagnostic tests (PAP smear and HPV test). Results: PAP smears were performed in 98.2% and HPV tests in 39.1% of all cases before histopathologic diagnosis. The most frequently detected high-risk HPV (hrHPV) was type 16. HPV testing significantly decreased with age. HPV testing was not performed in 74.2% of patients aged 51- 60 years and 80.9% of patients over 60 years. Conclusion: These cases the clinical utility and pathologic evaluation of the PAP smear were optimal. However, HPV testing practice was decreasing, especially with age. Cytologic evaluation may be misleading due to age-related hormonal withdrawal, difficulty in obtaining adequate smears, and atrophic changes. Our recommendation is to use HPV testing in all age groups, but especially in the population over 50 years of age, where cytologic difficulties may occur, HPV testing should be performed optimally until 65 years of age.

19 May 2023 in Free Radical Biology and Medicine
Verified
Journal Article
Open access
BKBusra Kose
Busra Kose
IDIrundika HK Dias
Irundika HK Dias
SESerkan Erkanli
Serkan Erkanli
AKAlper Kocak
Alper Kocak
ABAhmet Baykal
Ahmet Baykal